|
||
Duspacol 200 Actions |
||
Pharmacotherapeutic Group: Synthetic musculotropic antispasmodic with no anticholinergic activity, esters with tertiary amino group.
Pharmacology: Pharmacodynamics: Musculotropic antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract, relieving spasm without affecting normal gut motility. Since this action is not mediated by the autonomic nervous system, the usual anticholinergic side effects are absent.
Duspacol 200 Retard is suitable for patients with prostatic hypertrophy and glaucoma.
Clinical Efficacy and Safety: Duspacol 200: The clinical efficacy and safety of different formulations of mebeverine were evaluated in >1500 patients. Considerable improvements in the predominant symptoms of irritable bowel syndrome (eg, abdominal pain, stool characteristics) were generally observed in reference or baseline-controlled clinical studies.
All formulations of mebeverine were generally safe and well tolerated in the recommended dose regimen.
Pharmacokinetics: The prolonged-release formulation permits a twice daily dosing scheme.
Duspacol 200: Absorption: Mebeverine is rapidly and completely absorbed after oral administration of tablets.
Distribution: No significant accumulation occurs after multiple doses.
Biotransformation: Mebeverine hydrochloride is mainly metabolized by esterases, which initially split the ester bonds into veratric acid and mebeverine alcohol.
The main metabolite in plasma is demethylated carboxylic acid (DMAC). The steady state elimination half-life of DMAC is 2.45 hrs. During multiple dosing, the peak plasma concentration (Cmax) of DMAC for the coated tablets with 135 mg is 1670 ng/mL and time to reach the peak plasma concentration (tmax) is 1 hr.
Duspacol 200: Elimination: Mebeverine is not excreted as such, but metabolized completely; the metabolites are excreted nearly completely. Veratric acid is excreted into the urine, mebeverine alcohol is also excreted into the urine, partly as the corresponding carboxylic acid (MAC) and partly as the DMAC.
The primary mechanism of action of hexachlorophene, based on studies with Bacillus megatherium, is to inhibit the membrane-bound part of the electron transport chain, respiratory D-lactate dehydrogenase. It induces leakage, causes protoplast lysis, and inhibits respiration.
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|